Work Area: Valuation

Latest content

Beijing targets $54 billion in cross-border IP royalty flow by 2025

A new high-level policy calls for growth by a metric that includes not just royalty receipts but also payments to foreign IP owners

23 September 2021

Smartphone royalty stack continues multi-year decline, says analyst

Financial disclosures from four major publicly-listed patent owners suggest that their collective licensing revenues are on a downward trend

06 September 2021

Qualcomm licensing chief is number one in IAM's Market Makers ranking of the world's IP business leaders

The Long Read: Alex Rogers heads the list of individuals who have shaped the global patent licensing and deals markets over the past year, with senior executives from both corporates and NPEs making up the rest of the top 10

01 September 2021

Alibaba deploys tool to provide price guidance for patents going under the hammer

Intangio, developed by valuation specialists Inngot and IP services firm Rouse, is helping insolvency practitioners set a data-driven reserve price for patent assets at bankruptcy auctions

31 August 2021

IP could become a $100 billion premium market, says Aon CEO

Greg Case has been bullish about the sector for a while and if he is right it could finally mean the birth of the asset class so many have been waiting for

30 August 2021

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market

26 August 2021

Toyota’s self-driving haul from Lyft includes 100+ US patent assets

Patents change hands after Japanese carmaker buys Lyft’s self-driving tech for $550 million

23 August 2021

Japan’s corporate watchdog calls for high-level emphasis on intellectual property

Changes to the country’s corporate governance code encourage boards to pay more attention to IP strategy

18 August 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field

12 August 2021

Healthcare Royalty Partners’ $750 million IPO to be next milestone for a booming market

The company is hoping to raise cash to help expand its purchasing power when acquiring pharmaceuticals revenue streams

05 August 2021

Unlock unlimited access to all IAM content